Wang Qingying, Qin Jinlong, Chen Aozhen, Zhou Jianhong, Liu Jie, Cheng Jiajing, Qiu Jin, Zhang Jiawen
Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Middle Road, Shanghai, 200072, China.
Tumour Biol. 2015 May;36(5):3703-8. doi: 10.1007/s13277-014-3009-3. Epub 2015 Jan 6.
MicroRNAs (miRNAs) play important roles in the processes of tumor initiation and progression. However, miR-145 expression in cervical cancer has been rarely investigated. The aim of this study was to investigate the clinical significance and prognostic value of miR-145 expression in cervical cancer. MiR-145 expression in 114 pairs of human cervical cancer and adjacent normal tissues was detected by real-time quantitative RT-PCR assay. The results showed that miR-145 expression was significantly downregulated in cervical cancer tissues when compared with corresponding adjacent normal tissues (P < 0.001). It was also significantly lower in the cancerous tissues of patients with advanced International Federation of Gynecology and Obstetrics (FIGO) stage cervical cancer than those with early FIGO stage (P = 0.006). In addition, miR-145 was expressed at significantly lower levels in lymph node metastasis-positive patients than in lymph node metastasis-negative patients (P = 0.037). Moreover, poorly differentiated tumors expressed lower miR-145 than well or moderately differentiated tumors (P = 0.012). Patients with vascular invasion or human papillomavirus (HPV) infection also had lower miR-145 expression levels than those without (P = 0.016 and P = 0.025, respectively). Furthermore, Kaplan-Meier analysis showed that cervical cancer patients with low miR-145 expression had shorter overall survival time than those with high miR-145 expression (P < 0.001). When analyzed with a multivariate Cox regression model, miR-145 was identified as an independent prognostic factor for overall survival. Taken together, our results suggest that downregulation of miR-145 in cervical cancer is associated with aggressive progression and poor prognosis and that miR-145 may serve as a prognostic marker.
微小RNA（miRNA）在肿瘤发生和进展过程中发挥着重要作用。然而，miR-145在宫颈癌中的表达鲜有研究。本研究旨在探讨miR-145在宫颈癌中的临床意义及预后价值。采用实时定量逆转录聚合酶链反应（RT-PCR）检测114对人宫颈癌组织及癌旁正常组织中miR-145的表达。结果显示，与相应的癌旁正常组织相比，miR-145在宫颈癌组织中的表达显著下调（P < 0.001）。国际妇产科联盟（FIGO）晚期宫颈癌患者癌组织中的miR-145表达也显著低于FIGO早期患者（P = 0.006）。此外，淋巴结转移阳性患者的miR-145表达水平显著低于淋巴结转移阴性患者（P = 0.037）。而且，低分化肿瘤的miR-145表达低于高分化或中分化肿瘤（P = 0.012）。有血管侵犯或人乳头瘤病毒（HPV）感染的患者，其miR-145表达水平也低于无血管侵犯或HPV感染的患者（分别为P = 0.016和P = 0.025）。此外，Kaplan-Meier分析表明，miR-145低表达的宫颈癌患者总生存时间短于miR-145高表达患者（P < 0.001）。经多变量Cox回归模型分析，miR-145被确定为总生存的独立预后因素。综上所述，我们的结果表明，宫颈癌中miR-145的下调与侵袭性进展和不良预后相关，且miR-145可能作为一种预后标志物。
